Asciminib After Transplant or CAR T for Ph+ ALL
This study is looking at whether a drug called asciminib is safe and effective for adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL) to take after they've had either an allogeneic stem cell transplant (alloHCT) or CAR T-cell therapy. The main goal is to find the best dose of asciminib to use in future studies. You might be able to join if you are at least 18 years old, have Ph+ B-ALL in remission (meaning less than 5% cancer cells in your bone marrow), and meet other health requirements. The study plans to include 36 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. The study aims to determine the recommended Phase 2 dose of asciminib.
- What's involved
- Treatment with asciminib will be given on an outpatient basis. The primary endpoint, which is about the recommended dose, will be measured for up to 24 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint will be measured for up to 24 months after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Rawan Faramand, MD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Recommended Phase 2 DoseUp to 24 months
The MTD is defined as the highest dose level at which one or none of six patients experience a DLT.